These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 24347382)
1. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Becker A; Eichelberg C; Sun M Cancer; 2014 Jan; 120(1):7-10. PubMed ID: 24347382 [No Abstract] [Full Text] [Related]
2. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Halabi S; Rini BI; Escudier B; Stadler WM; Small EJ Cancer; 2015 Jun; 121(11):1906. PubMed ID: 25677867 [No Abstract] [Full Text] [Related]
3. Reply to progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Becker A; Eichelberg C; Sun M Cancer; 2015 Jun; 121(11):1906-7. PubMed ID: 25677986 [No Abstract] [Full Text] [Related]
4. Temsirolimus for advanced renal-cell carcinoma. Ferretti G N Engl J Med; 2007 Sep; 357(10):1050; author reply 1050-1. PubMed ID: 17823993 [No Abstract] [Full Text] [Related]
6. A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha. Bradshaw MJ; Cheville JC; Croghan GA Clin Adv Hematol Oncol; 2011 Jan; 9(1):61-4. PubMed ID: 21326149 [No Abstract] [Full Text] [Related]
7. Current treatment of renal cell carcinoma. De Mulder PH; van Herpen CM; Mulders PA Ann Oncol; 2004; 15 Suppl 4():iv319-28. PubMed ID: 15477330 [No Abstract] [Full Text] [Related]
13. High-dose interleukin-2 may not be superior to low-dose interleukin-2 plus interferon. Alikhan M; Spencer HJ; Kohli M J Clin Oncol; 2005 Sep; 23(25):6267-8; author reply 6268-9. PubMed ID: 16135500 [No Abstract] [Full Text] [Related]